Zim Laboratories vs Hester Biosciences vs Bharat Parenterals: Which Stock Should You Track

Zim Laboratories vs Hester Biosciences vs Bharat Parenterals starts with the core numbers most investors compare within the pharma and animal health segment: market capitalisation, valuation multiples, profitability, dividend yield and the latest quarterly results. Figures below are sourced as of October 2026 and will shift with daily price moves.

All three names sit in the pharma and animal health bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses. The sections below cover the company profiles, a valuation table, the latest quarter and a five-quarter trend for revenue and net profit.

Click Here – Get Free Investment Predictions

Zim Laboratories, Hester Biosciences and Bharat Parenterals: Company Overview

Zim Laboratories is a listed Indian company in the pharma and animal health space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 789 crore, a return on equity of 1.97% and a book value of Rs 54.77 per share. Its quarterly revenue moved from Rs 73.24 crore in June 2025 to Rs 95.17 crore in June 2026, a change of +29.9%.

Hester Biosciences is a listed Indian company in the pharma and animal health space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 1,802 crore, a return on equity of 15.45% and a book value of Rs 423.46 per share. Its quarterly revenue moved from Rs 86.43 crore in June 2025 to Rs 78.88 crore in June 2026, a change of -8.7%.

Bharat Parenterals is a listed Indian company in the pharma and animal health space, tracked here on book value, return ratios and valuation alongside its peers in this comparison. It has a market capitalisation of about Rs 1,305 crore, a return on equity of -2.54% and a book value of Rs 467.55 per share. Its quarterly revenue moved from Rs 117.06 crore in June 2025 to Rs 94.85 crore in June 2026, a change of -19.0%.

Zim Laboratories vs Hester Biosciences vs Bharat Parenterals: Valuation and Profitability Snapshot

Metric	Zim Laboratories	Hester Biosciences	Bharat Parenterals
Market Cap (approx.)	Rs 789 crore	Rs 1,802 crore	Rs 1,305 crore
PE Ratio (TTM)	213.04	13.16	NA
PB Ratio	2.68	5.00	4.05
Return on Equity (ROE)	1.97%	15.45%	-2.54%
EPS (TTM, Rs)	0.69	160.95	-43.52
Dividend Yield	0.00%	0.52%	0.05%
Debt to Equity	0.42	0.54	0.45
Book Value per Share (Rs)	54.77	423.46	467.55

Check the Univest Screener for Live Data

On valuation, Zim Laboratories trades at a PE of 213.04 and a PB of 2.68, Hester Biosciences at a PE of 13.16 and a PB of 5.00, while Bharat Parenterals trades at a PE of NA and a PB of 4.05. On return on equity, the three post 1.97%, 15.45% and -2.54% respectively, and on dividend yield they stand at 0.00%, 0.52% and 0.05%. Hester Biosciences has the highest market capitalisation of the three at Rs 1,802 crore, while Zim Laboratories has the lowest at Rs 789 crore. Zim Laboratories has the highest PE ratio of the three at 213.04, while Hester Biosciences has the lowest at 13.16. Hester Biosciences has the highest return on equity of the three at 15.45%, while Bharat Parenterals has the lowest at -2.54%. Hester Biosciences has the highest debt to equity ratio of the three at 0.54, while Zim Laboratories has the lowest at 0.42. Debt to equity is 0.42, 0.54 and 0.45 for the three respectively.

Zim Laboratories vs Hester Biosciences vs Bharat Parenterals: Latest Quarterly Results

Company	Latest Quarter Revenue	Latest Quarter Net Profit	YoY Change (Revenue)	QoQ Change (Revenue)	YoY Change (Net Profit)
Zim Laboratories	Rs 95.17 crore	-Rs 4.02 crore	+29.9%	-14.6%	NA
Hester Biosciences	Rs 78.88 crore	Rs 96.73 crore	-8.7%	-18.7%	+459.1%
Bharat Parenterals	Rs 94.85 crore	-Rs 3.56 crore	-19.0%	-8.1%	NA

Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter. A percentage change in net profit is shown as NA where the comparison quarter was a loss or the latest quarter is a loss, since the percentage is not meaningful in that case.

Zim Laboratories vs Hester Biosciences vs Bharat Parenterals: Five-Quarter Revenue and Net Profit Trend

The five-quarter view below shows how revenue and net profit moved from June 2025 to June 2026 for each company in Zim Laboratories vs Hester Biosciences vs Bharat Parenterals, which helps separate a one-quarter move from a steadier pattern.

Quarterly revenue (Rs crore)

Quarter	Zim Laboratories	Hester Biosciences	Bharat Parenterals
June 2025	Rs 73.24 crore	Rs 86.43 crore	Rs 117.06 crore
September 2025	Rs 90.75 crore	Rs 80.70 crore	Rs 68.15 crore
December 2025	Rs 110.36 crore	Rs 78.09 crore	Rs 66.52 crore
March 2026	Rs 111.43 crore	Rs 97.08 crore	Rs 103.25 crore
June 2026	Rs 95.17 crore	Rs 78.88 crore	Rs 94.85 crore

Quarterly net profit (Rs crore)

Quarter	Zim Laboratories	Hester Biosciences	Bharat Parenterals
June 2025	-Rs 1.87 crore	Rs 17.30 crore	-Rs 0.87 crore
September 2025	-Rs 0.42 crore	Rs 14.33 crore	-Rs 8.60 crore
December 2025	Rs 4.40 crore	Rs 9.31 crore	-Rs 9.67 crore
March 2026	Rs 3.74 crore	Rs 16.55 crore	-Rs 8.16 crore
June 2026	-Rs 4.02 crore	Rs 96.73 crore	-Rs 3.56 crore

Zim Laboratories reported revenue of Rs 73.24 crore in June 2025 and Rs 95.17 crore in June 2026, a change of +29.9% across the period. Its highest quarterly revenue in this window was Rs 111.43 crore in March 2026. Net profit stood at -Rs 4.02 crore in June 2026, which is a net profit margin of -4.22% (a net loss for the quarter). Zim Laboratories reported a net loss in June 2025, September 2025 and June 2026.

Hester Biosciences reported revenue of Rs 86.43 crore in June 2025 and Rs 78.88 crore in June 2026, a change of -8.7% across the period. Its highest quarterly revenue in this window was Rs 97.08 crore in March 2026. Net profit stood at Rs 96.73 crore in June 2026, which is a net profit margin of 122.63%.

Bharat Parenterals reported revenue of Rs 117.06 crore in June 2025 and Rs 94.85 crore in June 2026, a change of -19.0% across the period. Its highest quarterly revenue in this window was Rs 117.06 crore in June 2025. Net profit stood at -Rs 3.56 crore in June 2026, which is a net profit margin of -3.75% (a net loss for the quarter). Bharat Parenterals reported a net loss in June 2025, September 2025, December 2025, March 2026 and June 2026.

Download the Univest iOS App or Univest Android App to track Zim Laboratories, Hester Biosciences and Bharat Parenterals live prices.

What Should Investors Look at Beyond These Numbers?

Beyond the metrics above, investors comparing these three pharma and animal health names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and factors specific to the segment such as regulatory approvals, export demand, product mix, raw material costs and capacity utilisation. A single-quarter snapshot can shift quickly, and smaller companies in particular can show wide swings from one quarter to the next.

It also helps to read the latest quarterly filings and investor presentations of Zim Laboratories, Hester Biosciences and Bharat Parenterals directly, since the figures here come from standardised data and do not capture company-specific context such as one-time items, order timing or promoter actions.

Conclusion

Zim Laboratories vs Hester Biosciences vs Bharat Parenterals highlights how differently three companies in the same pharma and animal health segment can look across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.

FAQs on Zim Laboratories vs Hester Biosciences vs Bharat Parenterals

What is the market cap difference between Zim Laboratories, Hester Biosciences and Bharat Parenterals?

Ans. As of October 2026, Zim Laboratories has a market cap of approximately Rs 789 crore, Hester Biosciences is at approximately Rs 1,802 crore, and Bharat Parenterals is at approximately Rs 1,305 crore.

What are the PE and PB ratios of Zim Laboratories, Hester Biosciences and Bharat Parenterals?

Ans. As of October 2026, the PE ratios stand at 213.04, 13.16 and NA respectively, and the price to book ratios stand at 2.68, 5.00 and 4.05 respectively.

Which of the three has the highest ROE?

Ans. Zim Laboratories, Hester Biosciences and Bharat Parenterals post ROE of 1.97%, 15.45% and -2.54% respectively as of October 2026. Hester Biosciences has the highest return on equity of the three at 15.45%, while Bharat Parenterals has the lowest at -2.54%.

Which of these three stocks pays the highest dividend yield?

Ans. Zim Laboratories, Hester Biosciences and Bharat Parenterals carry dividend yields of 0.00%, 0.52% and 0.05% respectively.

What is the debt to equity ratio for Zim Laboratories, Hester Biosciences and Bharat Parenterals?

Ans. Zim Laboratories carries a debt to equity of 0.42, Hester Biosciences of 0.54, and Bharat Parenterals of 0.45.

What were the latest quarterly revenue and net profit of Zim Laboratories, Hester Biosciences and Bharat Parenterals?

Ans. For Q1 FY27 (quarter ended June 2026), Zim Laboratories reported revenue of Rs 95.17 crore and net profit of -Rs 4.02 crore, Hester Biosciences reported revenue of Rs 78.88 crore and net profit of Rs 96.73 crore, and Bharat Parenterals reported revenue of Rs 94.85 crore and net profit of -Rs 3.56 crore.

Does this comparison recommend one of Zim Laboratories, Hester Biosciences and Bharat Parenterals?

Ans. This comparison does not declare one stock ahead of another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.